Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 May 2023 | Story Leonie Bolleurs | Photo Supplied
Prof André Roodt
Prof Andreas Roodt was recently awarded the MT Steyn Prize for Natural Science and Technology Excellence from the SA Akademie vir Wetenskap en Kuns. He will receive the prize, sponsored by Sanlam, at a function scheduled for September this year.

Prof Andreas Roodt, former Head of the Department of Chemistry at the University of the Free State (UFS) and retired Distinguished Professor in the same department, was recently awarded the MT Steyn Prize for Natural Science and Technology Excellence from the SA Akademie vir Wetenskap en Kuns.

The prize, a major recognition of his life's work, was presented to him for his contribution to the exploration and sustained development of natural science and technology and the successful application thereof in broader society.

Impacting society

About receiving the prize, he says it was a big surprise, but he is very proud to be honoured with this special award, “being an Afrikaans kid from a ‘platteland’ school outside Bloemfontein.”

Prof Roodt’s research focuses on understanding the reaction mechanisms of mainly inorganic coordination chemical systems that are critical to different industrial, medical, environmental, and metal beneficiation processes.

His research, for instance, contributes to important compounds and processes relevant to nuclear medicine and potential cancer therapy. Not so long ago, he registered a patent on this in Europe, Japan, and the USA that could help to diagnose and potentially treat cancer-related tumours in the future.

In addition, he continues to work on several projects aimed at developing cleaner industrial processes in the South African petrochemical industry. He is also focusing on more efficient ways of accessing the country’s mineral resources.

Career highlights

Throughout his academic career, Prof Roodt has achieved many significant milestones. He was extensively involved in crystallography for more than 30 years. One of his career highlights was being elected as the President of the European Crystallographic Association from 2012 to 2015, an organisation with more than 35 member countries.

In this field, he established an X-ray crystallographic facility in the UFS Department of Chemistry, which was officially named the ‘Roodt XRD Lab’ at the end of 2021.

He also sees his journey with the diverse group of 41 PhD and 54 MSc students (Afrikaans, English, Sesotho, Setswana, and isiXhosa) as another notable achievement in his career.

Other outstanding moments in Prof Roodt's career were his collaborations with research leaders from countries such as the USA, UK, Switzerland, Italy, Sweden, France, Croatia, India, Japan, Russia, the Netherlands, Germany, and Tunisia. These collaborations have allowed him to be recognised by peers worldwide and have demonstrated that Africa and South Africa can produce high-quality and relevant research that can compete on an international level.

The future

Despite his appointment as a Distinguished Professor and his commitment to finishing uncompleted work and assisting younger colleagues both in South Africa and abroad, Prof Roodt retired more than a year ago. He is now enjoying his retirement with his wife, children, and grandchildren, while also devoting time to his passion for collecting aloe plants and generating new hybrids.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept